Zobrazeno 1 - 10
of 522
pro vyhledávání: '"sodium–glucose cotransporter‐2 inhibitor"'
Autor:
M. Soulié, Y. Stephan, M. Durand, I. Lima-Posada, R. Palacios-Ramírez, L. Nicol, N. Lopez-Andres, P. Mulder, F. Jaisser
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract Patients with chronic kidney disease (CKD) are at a high risk of cardiovascular (CV) complications. In these patients, sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been shown to reduce CV events. Mineralocorticoid receptor antagon
Externí odkaz:
https://doaj.org/article/15f1b047b07849c4b85225bbf161495d
Publikováno v:
Xin yixue, Vol 55, Iss 8, Pp 624-630 (2024)
Objective To evaluate clinical efficacy of early application of sodium-glucose cotransporter-2 （SGLT-2） inhibitors combined with standard therapy for readmission ST-segment elevation myocardial infarction （STEMI） patients complicated with hea
Externí odkaz:
https://doaj.org/article/1ba843be6ac849f98cc1967f7ef7d614
Autor:
Muhammad Shahzeb Khan, Janice P. Lea
Publikováno v:
BMC Nephrology, Vol 25, Iss 1, Pp 1-14 (2024)
Abstract Given the substantial burden of chronic kidney disease associated with type 2 diabetes, an aggressive approach to treatment is required. Despite the benefits of guideline-directed therapy, there remains a high residual risk of continuing pro
Externí odkaz:
https://doaj.org/article/d150c7a24bb44447a794c83bcf72ab52
Autor:
Tianhao Zhang, Xuelian Gao, Tianlong Chen, Hongkai Zhang, Xiaoming Zhang, Yu Xin, Dongmei Shi, Yu Du, Lei Xu, Yujie Zhou
Publikováno v:
Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-13 (2024)
Abstract Background Sodium–Glucose Cotransporter-2 Inhibitor (SGLT2i) is a novel oral drug for treating type 2 diabetes mellitus (T2DM) with demonstrated cardiovascular benefits. Previous studies in apolipoprotein E knockout mice have shown that SG
Externí odkaz:
https://doaj.org/article/4c9452ecb10d45bb956c25517c43325d
Publikováno v:
ESC Heart Failure, Vol 11, Iss 3, Pp 1647-1656 (2024)
Abstract Aims The study aims to provide comprehensive evidence for the selection of agents in type 2 diabetes mellitus (T2DM) patients with cardiovascular risk and summarize the lasted evidence for the cardiovascular effects of sodium glucose cotrans
Externí odkaz:
https://doaj.org/article/5509a21845ba41ccb1191149c0c6d527
Autor:
Nikita Ashcherkin, Abdelmohaymin A. Abdalla, Simran Gupta, Shubhang Bhatt, Claire I. Yee, Rodrigo Cartin-Ceba
Publikováno v:
Acute and Critical Care, Vol 39, Iss 2, Pp 251-256 (2024)
Background Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been shown to reduce organ dysfunction in renal and cardiovascular disease. There are limited data on the role of SGLT2i in acute organ dysfunction. We conducted a study to assess the
Externí odkaz:
https://doaj.org/article/bc5127fe20734e92b7a0344b914d3613
Publikováno v:
Frontiers in Endocrinology, Vol 15 (2024)
ObjectivesTo evaluate the efficacy and safety of non-steroid mineralocorticoid receptor antagonists (ns-MRAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) in patients with diabetic kidney disease (DKD).MethodsSystematic literature searches
Externí odkaz:
https://doaj.org/article/1e56d5cc64a34c0288eb3b564e8a18c8
Autor:
Sean A. Newsom, Matthew M. Robinson
Publikováno v:
Physiological Reports, Vol 12, Iss 11, Pp n/a-n/a (2024)
Abstract Regular exercise and antihyperglycemic drugs are front‐line treatments for type‐2 diabetes and related metabolic disorders. Leading drugs are metformin, sodium‐glucose cotransporter‐2 inhibitors, and glucagon‐like peptide 1 recepto
Externí odkaz:
https://doaj.org/article/e765697ce5ab48b68063d60e2e32c8dd
Autor:
Ju‐Hyun An, Han‐Sol Choi, Ji‐Soo Choi, Hyun‐Woo Lim, Wan Huh, Ye‐In Oh, Joon Seok Park, Jumi Han, Soo Lim, Chae‐Young Lim, Tae‐Hee Kim, Jae‐Bong Moon, Hwa‐Young Youn
Publikováno v:
Veterinary Medicine and Science, Vol 10, Iss 3, Pp n/a-n/a (2024)
Abstract Background Sodium‐glucose cotransporter‐2 (SGLT2) inhibitors are a novel class of anti‐hyperglycaemic agents. Objective This study aimed to evaluate the safety and the adjuvant glycaemic control effect of an SGLT2 inhibitor, DWP16001,
Externí odkaz:
https://doaj.org/article/af8d7451080f4b62a64fb9a42473ce91
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 9 (2024)
Background Both high and low levels of serum potassium measurements are linked with a higher risk of adverse clinical events among patients with type 2 diabetes. The study was aimed at evaluating the implications of the various degrees of initial est
Externí odkaz:
https://doaj.org/article/e30c058b45694ede946aa7565772d72d